Skinvisible Submits Innovative Obesity Patent for Advanced Transdermal Treatment

Contributed by: ACCESS Newswire

Tags

Healthcare & Pharmaceutical
OTCQB:SKVI
Skinvisible, Inc.
Product Announcements

More Like This

PR Newswire associated0

Tetra Pharm Technologies and Glysious Announce Collaboration to Develop Transdermal Combination Drugs Targeting the Endocannabinoid System

PR Newswire associated0

Daewoong Pharmaceutical to Initiate Clinical Trials Early Next Year for Innovative 'GLP-1 Obesity Treatment' with Advanced Microneedle Technology for Sustained Weekly Efficacy

Business Wire logo

Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo

Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation

First product based on LTS Sorrel™ wearable drug delivery platform launched in the US

PR Newswire associated0

Gan & Lee Pharmaceuticals Announces Significant Progress on New Diabetes and Obesity Treatments at the American Diabetes Association's 84th Scientific Sessions

Airfinity launches world’s first obesity data and analytics platform

PR Newswire associated0

Tetra Pharm Technologies advances CB1 antagonist, TPT0701, for appetite suppression into preclinical testing